

# Dose Optimization Study of Idelalisib in Follicular Lymphoma

**First published:** 08/09/2016

**Last updated:** 23/05/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS15094

---

### Study ID

33743

---


### DARWIN EU® study

No

---


### Study countries

 Australia

 Canada

 Czechia

 France

 Israel

 Italy

-  Poland
  -  Romania
  -  Spain
  -  United Kingdom
- 

## Study description

GS-US-313-1580: The study was terminated early due to enrollment challenges (after enrollment of 96 participants), therefore, the primary objective of the study to establish a safe and effective dosing regimen of idelalisib (IDL) in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options could not be determined.

---

## Study status

Finalised

# Research institutions and networks

## Institutions

### Gilead Sciences

**First published:** 12/02/2024

**Last updated:** 12/02/2024

**Institution**

**Pharmaceutical company**

**Multiple centres: 44 centres are involved in the study**

## Contact details

### Study institution contact

Gilead Study Director [ClinicalTrialDisclosure@gilead.com](mailto:ClinicalTrialDisclosure@gilead.com)

Study contact

[ClinicalTrialDisclosure@gilead.com](mailto:ClinicalTrialDisclosure@gilead.com)

### Primary lead investigator

Gilead Study Director

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 01/09/2015

Actual: 12/06/2015

---

### Study start date

Planned: 14/01/2016

Actual: 14/01/2016

---

### Date of interim report, if expected

Planned: 26/12/2017

Actual: 07/12/2017

---

### Date of final study report

Planned: 31/12/2026

Actual: 25/03/2023

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Gilead Sciences

## Study protocol

[amd-2-prot GS-US-313-1580-synopsis only.pdf](#) (194.63 KB)

[GS-US-313-1580-appendix-16.1.1-protocol Amendment 6\\_f-redact.pdf](#) (3.37 MB)

## Regulatory

### **Was the study required by a regulatory body?**

Yes

---

### **Is the study required by a Risk Management Plan (RMP)?**

Non-EU RMP only

## Methodological aspects

### Study type

### Study type list

### **Study topic:**

Disease /health condition

Human medicinal product

---

**Study type:**

Clinical trial

---

**Main study objective:**

Primary objective: To establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.

## Study Design

**Clinical trial randomisation**

Randomised clinical trial

## Study drug and medical condition

**Medical condition to be studied**

Follicular lymphoma

## Population studied

**Short description of the study population**

Patients aged 18 years or older diagnosed with relapsed or refractory lymphoma who had received at least 2 lines of prior therapy and have no other available therapeutic options randomized with the treatment arm of idelalisib.

Inclusion criteria:

- 1) Male or female  $\geq 18$  years of age
- 2) Histologically confirmed diagnosis of B-cell FL, and grade limited to 1, 2, or 3a based on criteria established by the World Health Organization (WHO) 2008 classification of tumors of hematopoietic and lymphoid tissues
- 3) Relapsed or refractory FL and have received at least 2 lines of prior therapy for FL and have no other available therapeutic options.
- 4) Ann Arbor Stage 2 (non-contiguous), 3, or 4 disease per Lugano Classification
- 5) Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy as determined by the IRC (defined as the presence of  $\geq 1$  lesion that measures  $\geq 1.5$  cm in the LD and  $\geq 1.0$  cm in the longest perpendicular dimension [LPD] as assessed by PET-CT, CT, or MRI).
- 6) Have adequate performance status (such as Eastern Cooperative Oncology Group [ECOG] Performance Status of  $\leq 2$  or Karnofsky Performance Status of  $\geq 60$ )
- 7) Required baseline laboratory data (within 4-weeks prior to start of study therapy) as shown in the table.
- 8) For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception during heterosexual intercourse from the signing of informed consent throughout the study treatment period and up to 30 days from the last dose of idelalisib.
- 9) For male subjects of reproductive potential having intercourse with females of childbearing potential, willingness to use a protocol-recommended method of contraception during heterosexual intercourse and to refrain from sperm donation throughout the study treatment period and for 90 days following discontinuation of idelalisib.
- 10) Lactating females must agree to discontinue nursing before study drug administration and until at least 30 days following last dose of idelalisib
- 11) Indicate willingness to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study

restrictions, including mandatory prophylaxis for PJ

12) Evidence of a signed informed consent indicating that the subject is aware of the neoplastic nature of their disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, possible side effects, potential risks and discomforts, and other pertinent aspects of study participation.

Exclusion Criteria:

- 1) History of lymphoid malignancy other than FL (eg, diffuse large B-cell lymphoma).
- 2) Known history of, or clinically apparent, central nervous system (CNS) lymphoma or leptomeningeal lymphoma.
- 3) Known presence of intermediate- or high-grade myelodysplastic syndrome.
- 4) Known history of serious allergic reaction including anaphylaxis or Stevens-Johnson syndrome/toxic epidermal necrolysis
- 5) History of a non-lymphoid malignancy except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for  $\geq$  1 year prior to enrollment, or any other cancer or malignancy that has been in complete remission for  $\geq$  5 years
- 6) Evidence of ongoing systemic infection (eg, bacterial, fungal, viral) at the time of enrollment
- 7) Known history of drug-induced liver injury, chronic active hepatitis B virus (HBV), chronic active hepatitis C virus (HCV), alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, portal hypertension, primary biliary cirrhosis, or ongoing extrahepatic obstruction caused by cholelithiasis
- 8) History of or ongoing drug-induced pneumonitis

- 9) History of or ongoing inflammatory bowel disease
  - 10) Known human immunodeficiency virus (HIV) infection
  - 11) CMV: Ongoing infection, treatment, or specifically CMV antiviral prophylaxis within 28 days prior to the Screening Visit CMV test
  - 12) Presence of any condition that could, in the opinion of the investigator, compromise the subject's ability to participate in the study, such as history of substance abuse, alcoholism, or a psychiatric condition
  - 13) History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
  - 14) Ongoing immunosuppressive therapy, including systemic corticosteroids (> 10 mg prednisone or equivalent/day) with the exception of the use of topical, enteric, or inhaled corticosteroids as therapy for comorbid conditions or systemic corticosteroids for autoimmune anemia and/or thrombocytopenia
  - 15) Concurrent participation in another therapeutic clinical study
  - 16) Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, electrocardiogram (ECG) finding, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject or impair the assessment of study results
  - 17) Prior treatment with PI3K inhibitors
- 

### **Age groups**

- Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)
- 

### **Special population of interest**

Other

---

## Special population of interest, other

Patients with follicular lymphoma

---

### Estimated number of subjects

96

## Study design details

### Outcomes

Overall response rate, Incidence of Grade ? 4 Treatment-Emergent Adverse Events (TEAEs), Duration of response, overall response rate by Week 24, Overall safety profile of idelalisib, time to onset of adverse events of interest (AEI), progression-free survival, overall survival, and idelalisib trough and peak plasma concentrations

---

### Data analysis plan

Data summaries involving continuous variables, data tables contained following information: sample size, mean, standard deviation (StD), standard error of the mean, median, minimum, and maximum. For categorical variables, the following information was presented: sample size, proportion, and 95% confidence intervals (CIs) based on exact binomial proportion. For the primary efficacy analysis, the ORR was estimated with 95% Clopper-Pearson exact CI provided.

## Documents

### Study results

[GS-US-313-1580 - CSR Synopsis\\_f-redact.pdf](#) (630.65 KB)

---

## Data management

## ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data sources (types)

Other

---

### Data sources (types), other

Prospective patient-based data collection

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

### Check conformance

Unknown

---

### Check completeness

Unknown

---

### Check stability

Unknown

---

**Check logical consistency**

Unknown

**Data characterisation**

**Data characterisation conducted**

No